62321-92-0Relevant academic research and scientific papers
CPAP-TUBULIN MODULE
-
Sheet 9/14, (2017/07/08)
The invention relates to CPAP-tubulin inhibitors having the general formula (1) or a physiologically acceptable salt thereof; and their use as cancer therapeutics.
FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS
-
Page/Page column 45; 47-48, (2010/11/26)
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, part
Fused tricyclic mGIuR1 antagonists as therapeutic agents
-
Page/Page column 22; 20, (2010/11/26)
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGlu
mGluR1 antagonists as therapeutic agents
-
Page/Page column 81, (2008/06/13)
In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
